- Details
- Art Rastinehad provides insight into the role of focal therapy in the treatment of prostate cancer. He begins the presentation with the evolution of prostate cancer care. He describes focal therapy in the context of the next significant opportunity in the treatment of prostate cancer once we have a positive biopsy and walks us through the why, the who the how and the where in defining focal therap...
|
- Details
- Phillip Koo hosts a lecture series which is being developed by the Prostate Cancer Outreach Working Group of the SNMMI. The Prostate Cancer Outreach Working Group focuses on increasing awareness of oncologists, urologists, and family practitioners about imaging and therapy technologies such as FACBC, bone scintigraphy, and radium-223. This lecture series will cover the complete spectrum of prostat...
|
- Details
- Nuclear Medicine physician at UCLA, Jeremie Calais joins Phillip Koo in discussion on PSMA based PET imaging, the state of the field at his facility, UCLA, advancements in previous years, and they take a deeper dive into the diagnostic and therapeutic setting of PSMA imaging and the outlook in the new year. Biographies: Jeremie Calais, MD, MSc Assistant Professor at the Ahmanson Translational Imag...
|
- Details
- Charles Ryan and Michael Hofman share in a discussion on the use of new imaging techniques in prostate cancer, the sensitivity of imaging and the use of theranostics PSMA targeted therapies for metastatic castrate-resistant prostate cancer. Michael Hofman details the quick advance of PSMA imaging in Australia. He highlights PSMA tracers including Gallium-68 and PSMA-Based [18F]DCFPyL PET/CT and th...
|
- Details
- Dr. May Sadik presents data from the SNMMI meeting highlighting a retrospective study in 45 patients with hormone naïve prostate cancer. The objective was to develop a completely automated method to quantify prostate gland update of 18F-choline in PET/CT images. The hope is that these preliminary data will lead to a better understanding of the relationship between this measure, the clinical data a...
|
- Details
- Suresh C. Srivastava presents the unique opportunities and future for nuclear medicine, including theragnostic radiopharmaceuticals for molecular imaging plus therapy and getting closer to personalized medicine, selection criteria, production, and the nuclear, physical, and chemical properties of certain dual-purpose radionuclides, including those that are currently being used, or studied and eval...
|
- Details
- Ur Metser a study that was conducted to determine whether integrated 18F-fluorocholine (FCH) PET whole-body MRI (PET/WBMRI) depicts lymph node and distant metastases in patients with high-risk prostate cancer more frequently than does conventional staging. Biography: Ur Metser, MD, FRCPC, Joint Department of Medical Imaging, the University of Toronto Related Content: 18F-Fluorocholine PET Whole-Bo...
|
- Details
- Claudia Zacharias presents Gallium 6 PSMA-11 PET/MR Imaging in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer, a pilot study evaluating the detection rate for the initial diagnosis of prostate cancer and the metastatic spread for patients in the intermediate and high-risk prostate cancer risk category using 68 Ga-PSMA-11 PET/MR. She reviews the potential role of 68 Ga-PSM...
|
- Details
- The 68Ga-PSMA PET/CT has a high clinical impact for preoperative staging, restaging biochemical recurrence after radical prostatectomy, and treatment monitoring. Dr. Chen highlights the details of this trial with two objectives. They assessed 68 Ga-PSMA PET/CT in primary prostate cancer with different clinical risks and further studied the inclusion of 11 C-Acetate PET/CT to see if there was an in...
|
- Details
- Radiolabeled prostate-specific membrane antigen (PSMA) has proven as a highly accurate method to detect recurrences and metastases of prostate cancer, but there are only sparse data about its diagnostic performance in primary prostate cancer. Manuela Hoffman presents a retrospective study of the diagnostic performance of 68Ga-PSMA PET/CT to detect significant prostate cancer in comparison with 18F...
|
